Skip to main content
Top

Nigella sativa powder for helicobacter pylori infected patients: a randomized, double-blinded, placebo-controlled clinical trial

Published in:

Abstract

Objective

This double-blind, placebo-controlled, clinical trial was conducted to define the effects of Nigella sativa (N. Sativa) powder plus conventional medical treatment of Helicobacter pylori (H. pylori) on serum ghrelin level and appetite in H. pylori-infected patients.

Methods

In the present study, 51 H. pylori-positive patients were randomly allocated to treatment (n = 26) or placebo (n = 25) groups. They received 2 g/day N. Sativa with quadruple therapy or 2 g/day placebo plus quadruple therapy for 8 weeks. The serum level of ghrelin was assessed before and after the intervention. Appetite was evaluated at the onset and at the end of the intervention.

Results

At the end of the study, the appetite of the treatment group improved significantly compared with the placebo group (P = 0.02). Statistically, the difference in serum ghrelin levels between the study’s groups was insignificant (P > 0.05).

Conclusion

Supplementation with N. Sativa powder may be a beneficial adjunctive therapy in H. pylori-infected patients.

Trial registration

This study was registered in the Iranian Registry of Clinical Trials (IRCT20170916036204N7) on 08/08/2018.
Title
Nigella sativa powder for helicobacter pylori infected patients: a randomized, double-blinded, placebo-controlled clinical trial
Authors
Hedieh Yousefnejad
Farzaneh Mohammadi
Mahvash Alizadeh-naini
Najmeh Hejazi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-03955-4
This content is only visible if you are logged in and have the appropriate permissions.